REGN Q3 deep dive: pipeline progress and core brands drive outperformance

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street's expectations in Q3 2026, with sales up 36.3% year on year to $5.12 billion. Its non-GAAP profit of $20.07 per share was 23.5% above analysts' consensus estimates.

Is now the time to buy REGN? Find out in our full research report (it's free).

Regeneron (REGN) Q3 2026 highlights:

• Revenue$5.12 billion vs S&P analysts' estimates of $4.60 billion (36.3% year-on-year growth, 11.1% beat)

• Adjusted EPS$20.07 vs S&P analysts' estimates of $16.25 (23.5% beat)

• Operating margin40%, up from 27.3% in the same quarter last year

• Market capitalization$92.65 billion

StockStory's take

Regeneron's third quarter was marked by strong commercial execution and pipeline momentum, with the company delivering results that topped Wall Street's revenue and profit expectations. Management credited growth to robust demand for its three core brands—DUPIXENT, EYLEA HD, and LIBTAYO—all of which hit new all-time sales highs. CEO Leonard Schleifer highlighted DUPIXENT's continued leadership across multiple indications and cited EYLEA HD's rapid adoption following recent label enhancements as key drivers. The company also benefited from its expanded collaboration with Sanofi and sustained momentum across existing and recent product launches.

Looking forward, Regeneron's forecast is shaped by late-stage pipeline progress and anticipated regulatory milestones, including the potential approval of cemdisiran for generalized myasthenia gravis. Management believes further growth will be underpinned by advancing next-generation type 2 inflammation antibodies, expanding indications for established brands, and initiating pivotal trials in obesity, metabolic, and rare diseases. CFO Chris Fenimore noted that increasing R&D investments are expected as the company moves over 15 programs into phase III trials this year, while cautioning that upward pressure on the company's tax rate and pricing dynamics in key franchises may affect future results.

Key insights from management's remarks

Management attributed the quarter's results to strong commercial uptake across multiple therapeutic areas and highlighted the advancement of several first-in-class pipeline candidates as foundational to future growth.

• DUPIXENT's broad momentum:Management reported that DUPIXENT's U.S. net sales exceeded $5 billion for the first time, driven by demand across all nine FDA-approved indications and favorable payer mix. Sanofi collaboration profits reached an all-time high due to this continued growth.

• EYLEA HD adoption accelerates:EYLEA HD saw a 20% sequential increase in physician demand, attributed to extended dosing intervals and recent label updates. The franchise benefited from anticipation of a prefilled syringe launch, which management believes will further support market share.

• LIBTAYO's oncology expansion:LIBTAYO's U.S. net sales increased 81% year-over-year, fueled by new indications in skin and lung cancers and positive clinical trial data in high-risk cutaneous squamous cell carcinoma. The brand is now the leading immunotherapy in non-melanoma skin cancers domestically.

• Pipeline advances:Regeneron advanced four distinct late-stage programs, including cemdisiran (siRNA therapy for myasthenia gravis), CIDEB (siRNA for metabolic liver disease), a novel antibody for POTS (postural orthostatic tachycardia syndrome), and ubamatamab (bispecific antibody for ovarian cancer). Each program is supported by genetics or clinical data, and pivotal trials are scheduled for the coming year.

• Sanofi alliance expansion:The amended antibody collaboration with Sanofi gives Regeneron equal profit-sharing in next-generation anti-inflammatory antibodies, providing a platform for future launches and lifecycle management beyond DUPIXENT.